BREAKING NEWS
FDA Greenlights BioNTech (NASDAQ:BNTX) and Pfizer’s Omicron Vaccine
In a significant development, the US Food and Drug Administration (FDA) has granted emergency use authorization to BioNTech (NASDAQ:BNTX) and Pfizer’s omicron-specific COVID-19 vaccine. This move is expected to provide a crucial boost to the global fight against the pandemic.
The FDA’s decision is based on the results of clinical trials, which showed that the vaccine was effective in preventing severe illness and hospitalization due to the omicron variant. The vaccine has also been shown to provide protection against hospitalization and severe illness caused by other COVID-19 variants.
"This is a significant milestone in our fight against COVID-19," said Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases. "The FDA’s authorization of this vaccine will help ensure that we have the tools we need to keep pace with the evolving pandemic and protect public health."
The vaccine will be distributed and administered by Pfizer, and will be available to individuals 12 years of age and older. It will be given in two doses, 21 days apart, and will be available at a wide range of locations, including pharmacies, clinics, and hospitals.
"We are thrilled to bring this new vaccine to the market," said Dr. Albert Bourla, Pfizer’s CEO. "We believe that it will be an important tool in the fight against COVID-19, and we are committed to making it available to as many people as possible."
KEY POINTS
- The FDA has granted emergency use authorization to BioNTech (NASDAQ:BNTX) and Pfizer’s omicron-specific COVID-19 vaccine.
- The vaccine has been shown to be effective in preventing severe illness and hospitalization due to the omicron variant.
- The vaccine will be available to individuals 12 years of age and older.
- It will be given in two doses, 21 days apart.
- The vaccine will be available at a wide range of locations, including pharmacies, clinics, and hospitals.
REACTORS
- "This is a major step forward in our fight against COVID-19," said Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases.
- "We are committed to making this vaccine available to as many people as possible," said Dr. Albert Bourla, Pfizer’s CEO.
SHARE THIS STORY
Facebook: https://www.facebook.com/sharer.php?u=https://www.grafalab.com/news/fda-greenlights-biontech-and-pfizers-omicron-vaccine/
Twitter: https://twitter.com/intent/tweet?text=FDA%20Greenlights%20BioNTech%20and%20Pfizer’s%20Omicron%20Vaccine&url=https://www.grafalab.com/news/fda-greenlights-biontech-and-pfizers-omicron-vaccine/
TAGS
- FDA
- BioNTech
- Pfizer
- Omicron
- COVID-19
- Vaccine
- Emergency Use Authorization
- National Institute of Allergy and Infectious Diseases
- Dr. Anthony Fauci
- Dr. Albert Bourla
- NASDAQ
- NYSE
- Grafa
- News
- Tech
- Healthcare
- Pharmaceuticals
- Pandemic
- Public Health
FDA Greenlights BioNTech (NASDAQ:BNTX) and Pfizer’s omicron vaccine #News #Tech #Nasdaq #NYSE #Grafa
View info-news.info by GrafaCharts